BURKITT LYMPHOMA TREATMENT MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Burkitt Lymphoma Treatment Market - Overview Burkitt Lymphoma Treatment Market, by Therapy Type (Chemotherapy, Targeted Therapy, and Radio-immunotherapy), by Route of Administration (Oral and Intravenous), by Disease Type (Endemic, Sporadic, and Immunodeficiency-associated), by End User (Hospitals, Clinics, and Ambulatory Surgical Centers), and by Geography - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026 Burkitt lymphoma is a cancer of the lymphatic system, which develops from abnormal B lymphocytes and is characterized by rapid growth. Burkitt lymphoma usually causes lymph node enlargement in various parts of the body, including spleen, liver, bone marrow, and central nervous system. Burkitt lymphoma is a type of high-grade non-Hodgkin lymphoma (NHL). The World Health Organization has classified Burkitt lymphoma as an endemic that affects children in Africa aged 4-7 years, sporadic that occurs globally, and immunodeficiencyassociated type that affects people suffering from HIV/AIDS. According to the survey by Cancer Therapy Advisor, Burkitt lymphoma accounts for 30% of pediatric lymphomas and less than 1% of lymphoma cases in adults, especially with a weakened immune system globally. The Burkitt lymphoma treatment market in Europe is expected to witness high growth, owing to increasing prevalence of sporadic form of Burkitt lymphoma in the U.K. According to the survey by Lymphoma Action Organization, 2015, around 210 people are affected by Burkitt lymphoma every year in the U.K. Browse Research Reports: https://www.coherentmarketinsights.com/ongoing-insight/burkittlymphoma-treatment-market-1547 Š Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Market Dynamics Rising incidence HIV is expected to augment growth of the Burkitt lymphoma treatment market, as Burkitt lymphoma is an AIDS-defining cancer that is expected to occur more frequently in people suffering from HIV than in the general population. According to the Burkitt Lymphoma Society, the condition accounts for an around 40% of all childhood non Hodgkin lymphoma patients worldwide. It also accounts for as many as 40% of all nonHodgkin lymphomas in HIV/AIDS patients. Also, according to the Cancer Therapy Advisor, Burkitt lymphoma (BL) is the most common pediatric cancer with the disease incidence being 2-3 times higher in sub-Saharan Africa, with an estimated incidence of 3–6 cases per 100,000 children per year. For instance, the National Cancer Institute initiated the Burkitt Lymphoma Genome Sequencing Project (BLGSP) to explore potential genetic changes in patients suffering from Burkitt lymphoma (BL) that could lead to better prevention, detection, and treatment of this rare and aggressive cancer. Moreover, researchers at Forgarty International Center and National Cancer Institute are working together to address global health needs related to various cancer types, including Burkitt lymphoma. Non-profit organization such as Burkitt Lymphoma Society supports and connects patients and caregivers by connecting the patients who have received efficient care for Burkitt lymphoma, thus providing information and creating awareness about the rare medical condition. Request a Sample copy of this reports : https://www.coherentmarketinsights.com/insight/request-sample/1547 Š Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION The presence of potential therapies for the prevention of Burkitt lymphoma is expected to augment the market growth over the forecast period. For instance, Viracta Therapeutics, Inc., initiated Phase 1 b/2 trial for Tractinostat in combination with Valganciclovir indicated for Epstein-Barr virus-positive (EBV+) lymphomas. According to the Cancer Research UK, 2015, around 200,000 new cases and over 140,000 deaths are estimated to be recorded each year due to EBV-associated cancers. Also, the National Cancer Institute initiated Phase 1 clinical trials for antibody therapy, directed against CD19- blinatumomab, a recombinant bispecific antibody in combination with Lenalidomide with Relapsed or Refractory Non-Hodgkin’s Lymphoma (NHL). Moreover, the FDA approved a radioimmunotherapy named Zevalin (Ibritumomab tiuxetan) in combination with a radioactive substance linked to a monoclonal antibody named rituximab, to treat patients suffering from certain types of non-Hodgkin lymphoma, including Burkitt lymphoma.
Regional segmentation of the global Burkitt lymphoma treatment market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global Burkitt lymphoma treatment market over the forecast period, owing to rising prevalence of lymphoma over the forecast period. Buy-Now this Research Report @
https://www.coherentmarketinsights.com/insight/buy-now/1547 Š Coherent market Insights. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele.
SERVICES INDUSTRY ANALYSIS
CUSTOMIZED RESEARCH
SYNDICATED RESEARCH
MARKET INTELLIGENCE SERVICES
CONSULT STUDIES
COUNTRY SPECIFIC STUDIES
Š Coherent market Insights. All Rights Reserved
ABOUT CMI SECTOR COVERAGE
BIOTECHNOLOGY
CLINICAL DIAGNOSTIC
HEALTHCARE IT
MEDICAL DEVICES
MEDICAL IMAGING
PHARMACEUTICAL
OUR CLIENTS
Global Leading Equipment and System Manufacturers Marketing Consultancies and the Advertising Industry Component Providers and System Integrators
Private and Government organization
Distributors, Retailors and Value Added Resellers
Outsourcing Companies
Healthcare IT Solutions Developers
Universities and Business Schools.
© Coherent market Insights. All Rights Reserved
KEY STATS
RESEARCH SOLUTIONS
100+
FEASIBILITY STUDIES
Insights Published Per Year
GLOBAL REPORTS
150+
Consulting Projects Till Date
COUNTRY ANALYSIS CONSULT PROJECTS
125+
Clients Worldwide Per Year
110+
SURVEY RESEARCH
EXCEL FORECAST DATABASE
CUSTOMIZED SOLUTIONS
COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS
Analysts and Contract Consultants
Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved
THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702
Š Coherent market Insights. All Rights Reserved